Load the Shotgun for Biotech
The biotech sector has been one of the standout performers in 2012. The sector has been buoyed by some key approvals at the FDA and by solid M&A activity. The sector has also benefited as it is not impacted by the ongoing crisis in Europe.
The M&A pace will continue to be strong as major pharma needs to replace and rebuild product pipelines they have not been able to fill organically, especially as the industry faces myriad blockbusters that will be coming off patent over the next several years....479 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.